Abbott Laboratories (ABT) Total Debt (2009 - 2026)

Abbott Laboratories has disclosed Total Debt across 18 years of filings, most recently posting $32.6 billion for Q2 2026.

• In Q2 2026, Total Debt rose 142.67% year-over-year to $32.6 billion; the TTM figure through Jun 2026 stood at $32.6 billion (up 142.67% YoY), while the FY2025 annual figure was $12.9 billion, down 17.25% from the prior year.
• Total Debt came in at $32.6 billion for Q2 2026 at Abbott Laboratories, down from $34.0 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $34.0 billion in Q1 2026 to a low of $12.9 billion in Q4 2025.
• Average Total Debt over 5 years is $17.4 billion, with a median of $15.7 billion recorded in 2023.
• Year-over-year, Total Debt slipped 17.25% in 2025 and jumped 157.11% in 2026.
• Over 5 years, Total Debt stood at $19.0 billion in 2022, then fell by 17.16% to $15.8 billion in 2023, then dropped by 0.85% to $15.6 billion in 2024, then declined by 17.25% to $12.9 billion in 2025, then surged by 152.21% to $32.6 billion in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $32.6 billion in Q2 2026, $34.0 billion in Q1 2026, and $12.9 billion in Q4 2025.